Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024

Neumora Therapeutics, Inc.

2024-Q3 EPS reported -$1.16

Cash and marketable securities $341.3M; operations funded into mid-2026.
Q3 R&D expenses $60.6M (vs $41.6M YoY); net loss $72.5M (vs $53.0M).
Phase 3 KOASTAL-1 navacaprant topline data expected around end of 2024.
KOASTAL-2/3 topline data H1 2025; navacaprant Phase 2 bipolar depression data H2 2025.
NMRA-511 Phase 1b AD agitation data H2 2025; M4 PAM IND submission expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.